Mendus Investor Relations Material

Mendus AB, a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. The company's main focus is on the development of prophylactic and therapeutic dendritic cell vaccines based on ilixadencel for the treatment of different solid tumor types. It is also involved in the development of INTUVAX, an allogeneic tumor cell vaccine to be used following surgery and anti-cancer therapy in patients with colorectal cancer or hepatocellular carcinoma to prevent recurrences.